TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 80 years (20 to 75 years in Japan)~* Written consent~* Diagnosis of adult onset Rheumatoid Arthritis (RA) of at least 3 months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria (Arnett et al, 1988)~* Treatment with methotrexate at a stable and tolerated doses~* Positive anti-cyclic citrullinated peptide (CCP) immuno-globulin G antibodies (more than \[\>\] 5 international unit per milliliter \[IU/mL\]) and/or rheumatoid factor (RF \>14 IU/mL) at screening~* Received more than or equal to (\>=) 5 milligram (mg) per week folic acid as a single or divided dose during the study.~Exclusion Criteria:~* A rheumatic autoimmune disease other than RA~* A history of, or current, inflammatory joint disease other than RA or other systemic autoimmune disorder~* Subjects at a high risk of infection~* Subjects (male and female) of reproductive potential who are not willing to use contraception from screening through the end date of the trial~* History of methotrexate or any drug-induced lung fibrosis or pneumonitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mavrilimumab 10 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 30 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 50 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Mavrilimumab 100 mg (Type: EXPERIMENTAL): Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a confirmed diagnosis of refractory epilepsy~* Patients must be receiving a stable dose of 1 - 3 concomitant Anti-Epileptic Drugs (AED)~* Female patients without childbearing potential. Female patients with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method~Exclusion Criteria:~* Seizures occurring in clusters~* Status epilepticus within 3 months of Visit 1~* History of non-epileptic seizures~* Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients~* Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, non-hormonal method of birth control

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Keppra® XR (Type: EXPERIMENTAL): Keppra® extended release formulation -XR
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients to receive video assisted thoracoscopic lobectomy or bullectomy .~Exclusion Criteria:~* 1. Patient refusal 2. Heavy skin eruption and infection at site of injection. 3. Coagulopathy. 4. Allergy to local anesthetics. 5. Taking analgesics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intercostal Nerve Block with PCIA (Type: ACTIVE_COMPARATOR): Intercostal Nerve Block with patient-controlled intravenous analgesia
- Erector Spinae Plane Block (ESPB) (Type: EXPERIMENTAL): Continuous Erector Spinae Plane Block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Stable fiber therapy~* Normal colonoscopy/sigmoidoscopy~* Able to refrain from use of medications known to treat or associated with constipation symptoms~* Experiences abdominal discomfort/pain associated with bowel movements~* Reports decreased bowel movement frequency and/or other symptoms associated with constipation~Exclusion Criteria:~* Diarrhea-predominant or alternating (diarrhea \& constipation cycling) IBS, or constipation other than that associated with IBS~* Open gastrointestinal or abdominal surgery prior to IBS onset~* Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, unexplained weight loss or rectal bleeding~* Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, other systemic disease, or abnormal laboratory tests per investigator discretion~* If female, is currently pregnant or nursing, or plans to become pregnant or nurse during the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonate has never had a clinical or surveillance culture grow S. aureus~* Neonate was transferred from another hospital or admitted from home and had admission screening cultures for S. aureus colonization that were negative (if admission cultures were not performed, the cultures will be performed as part of the pre-randomization screening process)~* Parent(s) is(are) able to visit the child at the bedside~* Parent(s) test positive for S. aureus at screening~* Neonate has anticipated stay longer than 5 days in the NICU (if estimated stay is unclear, parents can be screened for S. aureus colonization and decision to randomize can be delayed until hospital day 3 or 4 after reassessment of anticipated stay).~* Parents is(are) willing to be randomized~* No documented or reported allergies to any agent used in either treatment regimen~* Able to perform written informed consent~Exclusion Criteria:~* Allergies to any agent used in either treatment regimen~* Neonate has had a prior clinical or surveillance culture grow S. aureus~* Neonate admitted to NICU from home and is greater than 7 days of age~* Neonate admitted to NICU from another hospital and is greater than 7 days of age~* Neonate is a ward of the State~* Not able to provide written informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mupirocin and Chlorhexidine (Type: ACTIVE_COMPARATOR): Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
- Placebo ointment and placebo cloths (Type: PLACEBO_COMPARATOR): Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for enrollment into this study, subjects must meet all of the following criteria:~* Completion of study OB-303 (NCT00553787) on treatment and compliance with all protocol requirements~* Written informed consent~* Female subjects of childbearing potential must be using adequate contraception, defined as double-barrier methods, stable hormonal contraception plus single barrier method, or tubal ligation. Female subjects are considered to be of childbearing potential unless they have undergone a hysterectomy or bilateral oophorectomy, are ≥55 years of age and experienced spontaneous cessation of menses for at least 1 year, or have a documented follicle-stimulating hormone level ≥40 IU/L~* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~Exclusion Criteria:~Subjects will not be included in the study if they meet any of the following:~* Body mass index ≤22 kg/m2 at the completion of study OB-303~* Off study medication at completion of study OB-303 (NCT00553787) for longer than 4 weeks continuously due to an event-driven holiday, or off study medication with no plans to restart~* Development of any condition during study OB-303 (NCT00553787) that, in the opinion of the investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, or confound the interpretation of study results~* Participation in a formal weight loss program (including: Weight Watchers and related dietary/lifestyle intervention programs; prepared food programs; prescribed or over the counter weight loss medications; dietary supplement or herbal preparations, teas, or tinctures intended for weight loss; or any supervised fast or very low calorie diet).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- VI-0521 Mid (Type: EXPERIMENTAL): 7.5 mg phentermine and 46 mg topiramate
- VI-0521 Top (Type: EXPERIMENTAL): 15 mg phentermine and 92 mg topiramate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION:~* Relapsed or Refractory B cell lymphoma.~* Zubrod status \</= 3.~* Measurable disease.~* No anti-cancer treatment within past 3 weeks.~* ANC \>= 1500/uL, Plt \>/= 50,000, Bilirubin \<2 mg/dL, SGPT \<2.5xULN, creatinine \<2. Patients with ANC\>/1000, PLT\>/30000 will be eligible if due to massive splenomegaly and/or BM involvement.~* HIV negative.~* No active CNS lymphoma.~* No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma.~* Not eligible for treatment of a higher priority. Patients may be entered before BMT.~* No pregnancy \& age bearing females must be practicing adequate contraception.~* Age \> 16.~EXCLUSION:~* Patients with platelets \<30x10(9)/L within 14 days before enrollment.~* Patients with ANC\<1.0 x10(9)/L within 14 days before enrollment.~* Patients with peripheral neuropathy \>/= grade 3 within 14 days before enrollment.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (mantle-cell lymphoma) (Type: EXPERIMENTAL): None
- Arm B (other B-cell lymphomas) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemopreventive Therapy for Malaria in Ugandan Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 4 -5 months~2. Confirmed HIV status of biological mother~3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected mothers~4. Infants born to HIV-infected mothers must be breastfeeding~5. Residency within 30km of the study clinic~6. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol~7. Provision of informed consent by parent/guardian~Exclusion Criteria:~1. History of allergy or sensitivity to TS, SP, or DP~2. Active medical problem requiring in-patient evaluation at the time of screening~3. Intention of moving more that 30km from the study clinic during the follow-up period~4. Chronic medical condition (i.e. malignancy) requiring frequent medical attention~5. Living in the same household as a previously enrolled study participant~6. QTc interval \> 450 msec~7. Other clinically significant ECG abnormalities such as arrhythmia, ischemia, or evidence of heart failure~8. Family history of Long QT syndrome~9. Current use of drugs that prolong the QT interval

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 5 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Subjects must have signed and dated an IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care~* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study~* Patients with solid tumors treated with PD-1, PD-L1 and /or CTLA-4 inhibitors~* Diarrhea and/or colitis CTCAE grade ˃ 1 and/or arthritis CTCAE grade ˃ 1 induced by PD-1, PD-L1 and /or CTLA-4 inhibitors~* Age 18 years and older~* ECOG/WHO Performance Status (PS) 0-1, PS of 2 due to ongoing irAEs is allowed~* White blood cell count (WBC) ≥ 2 x 10⁹/L and/or absolute neutrophil count (ANC) ≥ 1.0 x 10⁹/L~* Platelet count ≥ 50 x 10⁹/L~* Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)~* ASAT/ALAT ≤ 5 x ULN~Exclusion Criteria:~* History of allergy to study drug component~* Patients should be excluded if they have a condition and/or other irAEs requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration~* Females of childbearing potential or males of reproductive potential who are not willing to use an effective method of contraception, such as oral, injected, or implanted hormonal methods of contraception, intrauterine device or intrauterine system, condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam, gel, film, cream, suppository, male sterilization, or true abstinence throughout study and for a minimum of 3 months after study drug therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \>50%~* sinus rhythm and stable clinical condition defined as no changes in therapeutic regimen, or hospitalization in the 6 months preceding recruitment.~* pulmonary artery systolic pressure \> 40 mm Hg,~Exclusion Criteria:~* Patients receiving nitrates~* A history of pulmonary disease~* Alternative causes of PH other than cardiac-related~* Renal failure (creatinine \> 2mg/dL)~* Anemia~* Pericardial disease~* Cardiac amyloidosis

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sildenafil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman aged 18 years or older~* Patient diagnosed with a visual impairment due to diabetic macular disease (as defined by HAS (Haute Autorité de Santé) recommendation).~* Patients in whom a decision to treat with intravitreal aflibercept has been made independently of the patient enrollment in the study~* Patient diagnosed with type 1 or 2 diabetes mellitus~* Patient who has been given appropriate information about the study and who has given his/her written, informed consent~Exclusion Criteria:~* Patient with other retinal disease at the time of inclusion~* Patients currently being treated with intravitreal aflibercept. This study will only include patients new to intravitreal aflibercept~* Systemic use of any anti / pro VEGF therapy (VEGF: Vascular Endothelial Growth Factor)~* Patient taking part in an interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Previously treated patient (Type: None): Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
- Naïve patient (Type: None): Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
- Entire study population (Type: None): Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete